A physician's guide for the management of hypertriglyceridemia: The etiology of hypertriglyceridemia determines treatment strategy

Panminerva Medica

Volumn 54, Issue 2, 2012, Pages 91-103

  Klop, B ^a   Wouter Jukema, J ^b   Rabelink, T J ^b   Castro Cabezas, M ^a  

^a SINT FRANCISCUS GASTHUIS   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoproteins b; Hyperlipidemias; Triglycerides

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

DIET; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE; METABOLISM; PRACTICE GUIDELINE; REVIEW;

DIET; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; TRIGLYCERIDES;

EID: 84862536619     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009;169:572-8.
2. Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med 2007;357:1009-17.
3. Pan X, Hussain MM. Gut triglyceride production. Biochim Biophys Acta 2011 [Epub ahead of print].
4. Mansbach CM, Siddiqi SA. The biogenesis of chylomicrons. Annu Rev Physiol 2010;72:315-33.
5. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009;296:E1183-94.
6. Leung GK, Véniant MM, Kim SK, Zlot CH, Raabe M, Björkegren J et al. A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion. J Biol Chem 2000;275:7515-20. (Pubitemid 30159647)
7. Klop B, Castro Cabezas M. Chylomicrons: a key biomarker and risk factor for cardiovascular disease and for the understanding of obesity. Curr Cardiovasc Risk Rep 2011;6:27-34.
8. Schaefer EJ, Wetzel MG, Bengtsson G, Scow RO, Brewer HB Jr, Olivecrona T. Transfer of human lymph chylomicron constituents to other lipoprotein density fractions during in vitro lipolysis. J Lipid Res 1982;23:1259-73. (Pubitemid 13165980)
9. Dallinga-Thie GM, Franssen R, Mooij HL, Visser ME, Hassing HC, Peelman F et al. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 2010;211:1-8.
10. 2Tu Y, Gin P, Weinstein MM et al. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab 2010;12:42-52.
11. Davies BS, Beigneux AP, Fong LG, Young SG. New wrinkles in lipoprotein lipase biology. Curr Opin Lipidol 2011 [E-pub ahead of print
12. Mahley RW, Huang Y, Rail SC, Jr. Pathogenesis of type IH hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999;40:1933-49. (Pubitemid 29523420)
13. Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vase Biol 2011;31:1716-25.
14. Jang Y, Kim JY, Kim OY, Lee JE, Cho H, Ordovas JM et al. The -1131T->C polymorphism in the apolipoprotein A5 gene is associated with postprandial hypertriacylglycerolemia; elevated small, dense LDL concentrations; and oxidative stress in nonobese Korean men. The American journal of clinical nutrition 2004;80:83240.
15. Bharadwaj KG, Hiyama Y, Hu Y, Huggins LA, Ramakrishnan R, Abumrad NA et al. Chylomicron- and VLDL-derived lipids enter the heart through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty acid uptake. J Biol Chem 2010;285:37976-86.
16. Goldberg IJ, Eckel RH, Abumrad NA. Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res 2009;50 Suppl:S86-90.
17. Kolovou GD, Anagnostopoulou KK, Kostakou PM, Mikhailidis DP. Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs. Curr Med Chem 2009;16:4345-60.
18. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333.
19. de Beer F, van Dijk KW, Jong MC, van Vark LC, van der Zee A, Hofker MH et al. Apolipoprotein E2 (Lys146->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides. Arterioscler Thromb Vase Biol 2000;20:1800-6. (Pubitemid 30470597)
20. Hara M, Iso-O N, Satoh H, Noto H, Togo M, Ishibashi S et al. Differential effects of apolipoprotein E isoforms on lipolysis of very low-density lipoprotein triglycerides. Metabolism 2006;55:112934.
21. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217(Suppl 1):l-44.
22. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9. (Pubitemid 26266496)
23. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008; 118:993-1001.
24. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16. (Pubitemid 47080485)
25. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299308.
26. Sharrett AR, Heiss G, Chambless LE, Boerwinkle E, Coady SA, Folsom AR et al. Metabolic and lifestyle determinants of postprandial lipemia differ from those of fasting triglycerides: The Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vase Biol 2001;21:275-81. (Pubitemid 32125378)
27. van Wijk JP, van Oostrom AJ, Castro Cabezas M. Normal ranges of non-fasting triglycerides in healthy Dutch males and females. Clin Chim Acta 2003;337:49-57. (Pubitemid 37329801)
28. Klop B, Conn JS, van Oostrom AJ, van Wijk JP, Birnie E, Castro Cabezas M. Daytime triglyceride variability in men and women with different levels of triglyceridemia. Clin Chim Acta 2011;412:2183-9.
29. Langsted A, Nordestgaard BG. Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals with and without Diabetes: 58 434 Individuals from the Copenhagen General Population Study. Clin Chem 2011;57:482-9.
30. Klop B, Proctor SD, Mamo JC, Botham KM, Castro Cabezas M. Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases. Int J Vase Med 2012;2012:947417.
31. Sniderman A, McQueen M, Contois J, Williams K, Furberg CD. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol 2010;4:152-5.
32. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;117:3002-9.
33. Arsenault BJ, Rana JS, Stroes ES, Després JP, Shah PK, Kastelein JJ et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009;55:35-41.
34. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118:2047-56.
35. Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP. Primary and secondary hypertriglyceridaemia. Curr Drug Targets 2009;10:336-43.
36. Lopez-Miranda J, Williams C, Lairon D. Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. Br J Nutr 2007;98:458-73. (Pubitemid 47272862)
37. Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 2001;24:443-56. (Pubitemid 32458079)
38. Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty BM et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000;101:2777-82. (Pubitemid 30396006)
39. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544-68.
40. Hopkins PN, Heiss G, Ellison RC, Hopkins PN, Heiss G, Ellison RC et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003;108:519-23. (Pubitemid 36961163)
41. Beigneux AP, Franssen R, Bensadoun A, Gin P, Melford K, Peter J et al. Chylomicronemia with a mutant GPIHBPl (Q1 15P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vase Biol 2009;29:956-62.
42. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147-55. (Pubitemid 13080348)
43. Castro Cabezas M, de Bruin TW, Erkelens DW. Familial combined hyperlipidaemia: 1973-1991. Neth J Med 1992;40:83-95.
44. Castro Cabezas M, de Bruin TW, Jansen H, Kock LA, Kortlandt W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb 1993;13:804-14. (Pubitemid 23164683)
45. Hegele RA, Ban MR, Hsueh N, Kennedy BA, Cao H, Zou GY et al. A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum Mol Genet 2009;18:4189-94.
46. Sabatti C, Service SK, Hartikainen AL, Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, Brodsky J et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet 2009;41:35-46.
47. Saxena R, Voight BF, Lyssenko V, Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331-6. (Pubitemid 46871653)
48. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13.
49. Wallace C, Newhouse SJ, Braund P, Zhang F, Tobin M, Falchi M et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 2008;82:139-49. (Pubitemid 351735954)
50. Wilier CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008;40:161-9. (Pubitemid 351171403)
51. Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem Erkelens D. Impaired fatly acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993;92:160-8. (Pubitemid 23208992)
52. Arai H, Ishibashi S, Bujo H, Hayashi T, Yokoyama S, Oikawa S et al. Management of Type lib dyslipidemia. J Atheroscler Thromb 2011 [E-pub ahead of print].
53. Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976;25:313-20.
54. Lopez-Miranda J, Perez-Martinez P, Marin C, Moreno JA, Gomez P, Perez-Jimenez F. Postprandial lipoprotein metabolism, genes and risk of cardiovascular disease. Curr Opin Lipidol 2006; 17:1328.
55. Deng LH, Xue P, Xia Q, Yang XN, Wan MH. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. World J Gastroenterol 2008;14:4558-61.
56. Cappell MS. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. Med Clin North Am 2008;92:889-923, ix-x. (Pubitemid 351822364)
57. Lloret Linares C, Pelletier AL, Czernichow S, Vergnaud AC, Bonnefont-Rousselot D, Levy P et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008;37:13-2.
58. Huang Y, Schwendner SW, Rail SC Jr, Sanan DA, Mahley RW Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. J Biol Chem 1997;272:22685-94. (Pubitemid 27386085)
59. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999;40:1-16. (Pubitemid 29022581)
60. Thuren T, Weisgraber KH, Sisson P, Waite M. Role of apolipoprotein E in hepatic lipase catalyzed hydrolysis of phospholipid in high-density lipoproteins. Biochemistry 1992;31:2332-8.
61. Thuren T, Wilcox RW, Sisson P, Waite M. Hepatic lipase hydrolysis of lipid monolayers. Regulation by apolipoproteins. J Biol Chem 1991;266:4853-61. (Pubitemid 21909433)
62. Kawashiri MA, Kobayashi J, Nohara A, Noguchi T, Tada H, Nakanishi C et al. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study. Clin Chim Acta 2011;412:1068-75.
63. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-80. (Pubitemid 46028447)
64. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Bodymass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-105. (Pubitemid 29466221)
65. Halkes CJ, Van Wijk JP, Ribalta J, Masana L, Castro Cabezas M. Diurnal triglyceridaemia and insulin resistance in mildly obese subjects with normal fasting plasma lipids. J Intern Med 2004;255:7481.
66. Yki-Jarvinen H, Taskinen MR. Interrelationships among insulin's antilipolytic and glucoregulatory effects and plasma triglycerides in nondiabetic and diabetic patients with endogenous hypertriglyceridemia. Diabetes 1988;37:1271-8. (Pubitemid 19035061)
67. Karpe F, Bickerton AS, Hodson L, Fielding BA, Tan GD, Frayn KN. Removal of triacylglycerols from chylomicrons and VLDL by capillary beds: the basis of lipoprotein remnant formation. Biochem Soc Trans 2007;35:472-6. (Pubitemid 46975055)
68. Taskinen MR, Adieis M, Westerbacka J, Soderlund S, Kahri J, Lundbom N et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vase Biol 2011;31:2144-50.
69. Eckel RH. The complex metabolic mechanisms relating obesity to hypertriglyceridemia. Arterioscler Thromb Vase Biol 2011;31:1946-8.
70. Goldberg RB, Capuzzi D. Lipid disorders in type 1 and type 2 diabetes. Clin Lab Med 2001;21:147-72, vii. (Pubitemid 32289932)
71. Marques-Vidal P, Cambou JP, Nicaud V, Luc G, Evans A, Arveiler D et al. Cardiovascular risk factors and alcohol consumption in France and Northern Ireland. Atherosclerosis 1995; 115:225-32.
72. Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ 2011;342:d636.
73. Ruidavets JB, Ducimetière P, Evans A, Montaye M, Haas B, Bingham A et al. Patterns of alcohol consumption and ischaemic heart disease in culturally divergent countries: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). BMJ 20l0;341:c6077.
74. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993;329:1829-34. (Pubitemid 23360481)
75. Naissides M, Mamo JC, James AP, Pal S. The effect of acute red wine polyphenol consumption on postprandial lipaemia in postmenopausal women. Atherosclerosis 2004;177:401-8. (Pubitemid 39505274)
76. van ToI A, van der Gaag MS, Scheek LM, van Gent T, Hendriks HF. Changes in postprandial lipoproteins of low and high density caused by moderate alcohol consumption with dinner. Atherosclerosis 1998;141(Suppl 1):S101-3.
77. Baraona E, Lieber CS. Alcohol and lipids. Recent Dev Alcohol 1998;14:97-134.
78. Fielding BA, Reid G, Grady M, Humphreys SM, Evans K, Frayn KN. Ethanol with a mixed meal increases postprandial triacylglycerol but decreases postprandial non-esterified fatty acid concentrations. Br J Nutr 2000;83:597-604. (Pubitemid 30392099)
79. Mero N, Syvanne M, Eliasson B, Smith U, Taskinen MR. Postprandial elevation of ApoB-48-containing triglyceride-rich particles and retinyl esters in normolipemic males who smoke. Arterioscler Thromb Vase Biol 1997;17:2096-102. (Pubitemid 28057113)
80. Pearce EN. Hypothyroidism and dyslipidemia: modern concepts and approaches. Curr Cardiol Rep 2004;6:451-6. (Pubitemid 39585763)
81. Duntas LH. Thyroid disease and lipids. Thyroid 2002;12:287-93. (Pubitemid 34438931)
82. Teixeira Pde F, Reuters VS, Ferreira MM, Almeida CP, Reis FA, Buescu A et al. Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failure. Transi Res 2008;151:224-31. (Pubitemid 351384829)
83. Friis T, Pedersen LR. Serum lipids in hyper- and hypothyroidism before and after treatment. Clin Chim Acta 1987;162:155-63. (Pubitemid 17022580)
84. van Wijk JP, Castro Cabezas M. Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. Int J Vase Med 2012;2012:201027.
85. Vaziri ND. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial 2009;22:644-51.
86. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290:F262-72. (Pubitemid 43724980)
87. Crowe FL, Roddam AW, Key TJ, Appleby PN, Overvad K, Jakobsen MU et al. Fruit and vegetable intake and mortality from ischaemic heart disease: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study. Eur Heart J 2011;32:1235-43.
88. Zampelas A, Peel AS, Gould BJ, Wright J, Williams CM. Polyunsaturated fatty acids of the n-6 and n-3 series: effects on postprandial lipid and apolipoprotein levels in healthy men. Eur J Clin Nutr 1994;48:842-8.
89. Lozano A, Perez-Martinez P, Delgado-Lista J, Marin C, Cortes B, Rodriguez-Cantalejo F et al. Body mass interacts with fat quality to determine the postprandial lipoprotein response in healthy young adults. Nutr Metab Cardiovasc Dis 2012;22:355-61.
90. Lairon D. Macronutrient intake and modulation on chylomicron production and clearance. Atheroscler Suppl 2008;9:45-8.
91. Mortensen LS, Hartvigsen ML, Brader LJ, Astrup A, Schrezenmeir J, Hoist JJ, Thomsen et al. Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein. Am J Clin Nutr 2009;90:41-8.
92. Khossousi A, Binns CW, Dhaliwal SS, Pal S. The acute effects of psyllium on postprandial lipaemia and thermogenesis in overweight and obese men. Br J Nutr 2008;99:1068-75.
93. Lairon D, Play B, Jourdheuil-Rahmani D. Digestible and indigestible carbohydrates: interactions with postprandial lipid metabolism. The Journal of nutritional biochemistry 2007;18:217-27. (Pubitemid 46389579)
94. Harbis A, Perdreau S, Vincent-Baudry S. Glycemie and insulinemic meal responses modulate postprandial hepatic and intestinal lipoprotein accumulation in obese, insulin-resistant subjects. Am J Clin Nutr 2004;80:896-902. (Pubitemid 41202088)
95. Basu A, Lucas EA. Mechanisms and effects of green tea on cardiovascular health. Nutr Rev 2007;65:361-75. (Pubitemid 351804352)
96. Burton-Freeman B, Linares A, Hyson D, Kappagoda T. Strawberry modulates LDL oxidation and postprandial lipemia in response to high-fat meal in overweight hyperlipidemic men and women. J Am Coll Nutr 2010;29:46-54.
97. Maraki MI, Aggelopoulou N, Christodoulou N, Anastasiou CA, Toutouza M, Panagiotakos DB et al. Lifestyle intervention leading to moderate weight loss normalizes postprandial triacylglycerolemia despite persisting obesity. Obesity (Silver Spring) 2011;19:968-76.
98. Mestek ML. Physical activity, blood lipids, and lipoproteins. Am J Lifestyle Med 2009;3:279-83.
99. Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 2003;37:283-90. (Pubitemid 37162679)
100. Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010;210:35-40.
101. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995;95:705-12.
102. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vase Biol 2008;28:39-46.
103. Tremblay AJ, Lamarche B, Ruel IL, Hogue JC, Deshaies Y, Gagné C et al. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia. Atherosclerosis 2006;188:203-12. (Pubitemid 44142545)
104. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 2008;57:380-6. (Pubitemid 351178728)
105. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66B-9B. (Pubitemid 28113949)
106. Group TCDPR. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
107. Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142:95-104.
108. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990;264:30137.
109. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2008;48:79-106. (Pubitemid 351738150)
110. Vosper H. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol 2009;158:429-41.
111. Mahboubi K, Witman-Jones T, Adamus JE, Letsinger JT, Whitehouse D, Moorman AR et al. Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74. Biochem Biophys Res Commun 2006;340:482-90. (Pubitemid 43021774)
112. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vase Biol 1999;19:1051-9. (Pubitemid 29177355)
113. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008;197:12-24.
114. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 2006;17:387-93. (Pubitemid 44079475)
115. Yoshikawa T, Shimano H, Yahagi N, Ide T, Amemiya-Kudo M, Matsuzaka T et al. Polyunsaturated fatty acids suppress sterol regulatory element-binding protein Ic promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J Biol Chem 2002;277:1705-11. (Pubitemid 34968740)
116. Kast HR, Nguyen CM, Sinai CJ. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001;15:1720-8. (Pubitemid 32939302)
117. Claudel T, Inoue Y, Barbier O. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003;125:544-55. (Pubitemid 36929436)
118. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003;44:45563.
119. Khan S, Minihane AM, Talmud PJ. Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res 2002;43:979-85. (Pubitemid 34602621)
120. Dujovne CA, Williams CD, Ito MK. What combination therapy with a statin, if any, would you recommend? Curr Atheroscler Rep 2011;13:12-22.
121. Rubenfire M, Brook RD, Rosenson RS. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med 2010; 123:892-8.
122. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009;53:316-22.
123. Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 2008;57:796-801. (Pubitemid 351697911)
124. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ et al. Effects of fibrates on cardiovascular outcomes: a systematic review and metaanalysis. Lancet 2010;375:1875-84.
125. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol 2008; 153 Suppl 1:S68-75. (Pubitemid 351340990)
126. Guyton JR. Treatment of type III hyperlipoproteinemia. Am Heart J 1999;138:17-8. (Pubitemid 29331114)
127. Civeira F, Cenarro A, Ferrando J. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. Am Heart J 1999; 138:156-62. (Pubitemid 29331137)
128. Illingworth DR, O'Malley JP. The hypolipidemic effects of lovastatin and Clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism 1990;39:403-9. (Pubitemid 20146593)
129. Cho EJ, Min YJ, Oh MS, Kwon JE, Kim JE, Kim CJ. Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia. Am J Cardiol 2011; 107:793-6.
130. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995;92:1779-85.
131. Rubins HB, Robins SJ, Collins D. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VAHIT). Arch Intern Med 2002;162:2597-604. (Pubitemid 35453499)
132. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-60. (Pubitemid 40720740)
133. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
134. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
135. Otvos JD, Collins D, Freedman DS. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-63. (Pubitemid 43739414)
136. Barter PJ, Rye KA. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? Circulation 2006;113:1553-5. (Pubitemid 43739413)